Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$94.35 USD

94.35
239,975

+0.59 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.

MMSI vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

MMSI vs. ALGN: Which Stock Is the Better Value Option?

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Buy Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.

Alcon (ALC) Gains From Innovation, Faces FX Challenges

by Zacks Equity Research

Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.

Here's Why You Should Retain Ecolab (ECL) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business

by Zacks Equity Research

Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.

Amedisys (AMED) Faces Macro Challenges, Margin Pressure

by Zacks Equity Research

The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.

Walgreens Boots (WBA) Q1 Earnings Top, Revenues View Up

by Zacks Equity Research

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

Masimo's (MASI) SpHb During Elective CS Favored by New Study

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Walgreens' (WBA) strategic executions on both the United States and the international front are likely to have contributed to the Q1 2023 top line.

Teleflex (TFX) OEM Arm Grows, Supply Issue Persists

by Zacks Equity Research

From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.

Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

by Zacks Equity Research

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.

Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue

by Zacks Equity Research

Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.

3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth

by Zacks Equity Research

Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX), led by the continued strength of the GYN Surgical business.

3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.